Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
about
Enhancing Cancer Immunotherapy Via Activation of Innate ImmunityNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis.NK cell-based immunotherapies in Pediatric Oncology.Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Immunocytokines for cancer treatment: past, present and future.Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.The sweet side of tumor immunotherapy.Development of antibody therapeutics for small cell lung cancer.Immunocytokines: a review of molecules in clinical development for cancer therapy.Delivering safer immunotherapies for cancer.Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.Immunocytokines
P2860
Q26796313-40B938C3-0B1F-4BEA-8077-E9A31200FDF2Q26797345-8FD9C925-AB66-4653-ABA2-396D8736A08EQ33811204-79FDB335-8E45-453A-9501-2C64BA8C1AB9Q35031732-98E5AC5C-1393-4733-90B9-D57ECD263C90Q35077925-73C34A78-F67B-44FC-B557-C38FA6B8010EQ35600975-8AFBE0FD-83FB-49AE-9FA9-C0C16C8F9CBCQ35603066-9D06A9BF-BB46-4C5F-A9AB-EA196CE6C970Q35963440-E3C05A7E-C2BF-43B9-A5B7-BB66D7899C11Q36179663-1C89546A-005B-46D3-BAED-FAE9601FF20FQ37059790-D8C00BD9-3055-4665-A0E1-FB81F99D68A0Q37560208-FC8854E4-7EC9-4317-9364-B9F72BF83E43Q37637949-B39C93DA-C4F5-4E25-9DCC-714CCEDE0512Q38031282-922D2B0E-3B32-4D54-95D5-09844B2ECE2DQ38061969-72DF971E-4585-4A56-82AF-020E050AAFBBQ38132742-FF020086-A6CE-4828-96D1-9F02F717FD77Q39330984-7C316EC8-445A-40AF-8EE8-3B1A68EAEFB0Q42336210-103675DD-F792-4059-92EC-742A16DEEE5DQ47311471-A2875176-1561-49C0-9C1A-6EF7DF1C423BQ50034069-7DC67405-FFD7-4895-8E6F-9CD5317F5EFEQ50545440-06D4F375-B4E6-404C-A9F6-645DB327D930Q50962872-F4633420-65EF-474B-8B94-73ADE7D7B299Q51786117-55B69B38-0B1C-48BE-986F-8979C2F5CCB7Q52565554-D2168CE1-33A1-44DB-91EA-2256F427C686Q57911975-8C5BC1C4-544A-4B9A-8C80-5458C24E7218
P2860
Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@ast
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@en
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@nl
type
label
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@ast
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@en
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@nl
prefLabel
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@ast
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@en
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@nl
P2093
P2860
P1476
Ab-IL2 fusion proteins mediate ...... cell-effector cell interface.
@en
P2093
Arvinder K Kapur
Brian Gadbaw
Dhara Patel
Ilia N Buhtoiarov
Jacquelyn A Hank
Jennifer A A Gubbels
Joseph Connor
Manish S Patankar
Paul M Sondel
Sachi Horibata
P2860
P2888
P304
P356
10.1007/S00262-011-1072-9
P577
2011-07-27T00:00:00Z
P6179
1033254523